Renal failure and gadolinium

Prescrire International

Volumn 17, Issue 97, 2008, Pages 205-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE;

CHRONIC KIDNEY FAILURE; DRUG MONITORING; DRUG SAFETY; FRANCE; HUMAN; KIDNEY FAILURE; KIDNEY FIBROSIS; NEPHROGENIC SYSTEMIC FIBROSIS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING;

CONTRAST MEDIA; FRANCE; GADOLINIUM; GADOLINIUM DTPA; HUMANS; KIDNEY FAILURE; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 67649401871     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (3)

1. Afssaps "Information importante de pharma-covigilance. Magnevist et fibrose systémique néphrogénique (FSN)" June 2007. Afssaps.sante.fr accessed 9 July 2007: 2 pages.
2. Prescrire Editorial Staff "Renal failure and gadolinium: nephrogenic systemic nephrosis" Prescrire Int 2007; 16 (63): 18.
3. "Important Drug Warning for gadolinium-based contrast agents" 12 September 2007. www.fda.gov accessed 18 December 2007: 4 pages.